National Health Investors, Inc.

NYSE:NHI Stock Report

Market Cap: US$3.5b

National Health Investors Valuation

Is NHI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NHI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NHI ($77.14) is trading below our estimate of fair value ($138.29)

Significantly Below Fair Value: NHI is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for NHI?

Key metric: As NHI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NHI. This is calculated by dividing NHI's market cap by their current earnings.
What is NHI's PE Ratio?
PE Ratio27.7x
EarningsUS$126.68m
Market CapUS$3.54b

Price to Earnings Ratio vs Peers

How does NHI's PE Ratio compare to its peers?

The above table shows the PE ratio for NHI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average45.6x
SBRA Sabra Health Care REIT
44.8x18.8%US$4.4b
CTRE CareTrust REIT
58.1x45.5%US$5.8b
LTC LTC Properties
17.3x-4.7%US$1.7b
SILA Sila Realty Trust
62.1x8.4%US$1.4b
NHI National Health Investors
27.7x10.8%US$3.5b

Price-To-Earnings vs Peers: NHI is good value based on its Price-To-Earnings Ratio (27.7x) compared to the peer average (45.6x).


Price to Earnings Ratio vs Industry

How does NHI's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
NHI 27.7xIndustry Avg. 26.5xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NHI is expensive based on its Price-To-Earnings Ratio (27.7x) compared to the Global Health Care REITs industry average (26.7x).


Price to Earnings Ratio vs Fair Ratio

What is NHI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NHI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio27.7x
Fair PE Ratio36.6x

Price-To-Earnings vs Fair Ratio: NHI is good value based on its Price-To-Earnings Ratio (27.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NHI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$77.14
US$85.00
+10.2%
7.1%US$92.00US$77.00n/a7
Nov ’25US$76.45
US$85.86
+12.3%
7.0%US$92.00US$76.00n/a7
Oct ’25US$83.01
US$84.71
+2.1%
9.6%US$92.00US$68.00n/a7
Sep ’25US$81.43
US$80.67
-0.9%
8.7%US$90.00US$68.00n/a6
Aug ’25US$74.71
US$70.17
-6.1%
7.4%US$80.00US$65.00n/a6
Jul ’25US$67.53
US$68.83
+1.9%
5.7%US$74.00US$63.00n/a6
Jun ’25US$66.08
US$66.50
+0.6%
7.3%US$73.00US$58.00n/a6
May ’25US$63.40
US$62.83
-0.9%
8.4%US$69.00US$54.00n/a6
Apr ’25US$61.75
US$62.33
+0.9%
9.3%US$69.00US$54.00n/a6
Mar ’25US$57.70
US$61.00
+5.7%
9.5%US$69.00US$54.00n/a7
Feb ’25US$53.58
US$57.86
+8.0%
8.5%US$69.00US$54.00n/a7
Jan ’25US$55.85
US$56.00
+0.3%
3.6%US$60.00US$54.00n/a6
Dec ’24US$55.82
US$55.00
-1.5%
4.1%US$60.00US$52.00n/a7
Nov ’24US$50.23
US$54.86
+9.2%
3.4%US$58.00US$52.00US$76.457
Oct ’24US$51.36
US$55.00
+7.1%
3.6%US$58.00US$52.00US$83.016
Sep ’24US$51.77
US$56.50
+9.1%
2.7%US$58.00US$54.00US$81.434
Aug ’24US$54.85
US$57.25
+4.4%
3.8%US$60.00US$54.00US$74.714
Jul ’24US$52.42
US$57.25
+9.2%
3.8%US$60.00US$54.00US$67.534
Jun ’24US$52.43
US$55.60
+6.0%
6.2%US$60.00US$50.00US$66.085
May ’24US$49.36
US$55.20
+11.8%
6.7%US$60.00US$50.00US$63.405
Apr ’24US$51.58
US$57.00
+10.5%
6.8%US$61.00US$50.00US$61.755
Mar ’24US$53.73
US$58.80
+9.4%
3.6%US$61.00US$55.00US$57.705
Feb ’24US$59.02
US$60.83
+3.1%
7.6%US$68.00US$55.00US$53.586
Jan ’24US$52.22
US$61.50
+17.8%
6.5%US$68.00US$58.00US$55.856
Dec ’23US$55.64
US$60.00
+7.8%
12.2%US$68.00US$47.00US$55.825
Nov ’23US$55.50
US$61.67
+11.1%
11.8%US$70.00US$47.00US$50.236

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies